Healthcare & Life Sciences
Salvina Therapeutics
About
Salvina Therapeutics has identified a novel epitope for selectively targeting TNF and other TNF superfamily members and is developing antibodies with a novel mode of action intended to improve the benefit/risk profile of TNF targeting and enable bispecific therapies.
Explore Salvina Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.